Effects of Abciximab as adjunctive therapy in primary percutaneous coronary intervention patients (results from the DANAMI-2 trial)

Acute Cardiac Care

Volumn 8, Issue 2, 2006, Pages 75-82

  Sejersten, Maria ^a,c   Maynard, Charles ^b   Clemmensen, Peter ^a  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Rigshospitalet   (Denmark)

Author keywords

Abciximab; Outcome; Primary percutaneous coronary intervention; ST segment resolution

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CARDIAC PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; DRUG EFFECT; FEMALE; FOLLOW UP; GROUPS BY AGE; HEART MUSCLE REPERFUSION; HEART REINFARCTION; HIGH RISK POPULATION; HOSPITAL; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MICROVASCULATURE; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL DISABILITY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; REMISSION; ST SEGMENT ELEVATION; STATISTICAL ANALYSIS; STROKE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOPLASTY, BALLOON, CORONARY; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CORONARY CIRCULATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 33745813911     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.1080/14628840600648200     Document Type: Article

References (32)

1. van't Hof AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet. 1997;350:615-9.
2. Claeys MJ, Bosmans J, Veenstra L, Jorens P, De R, Vrints CJ. Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: importance of microvascular reperfusion injury on clinical outcome. Circulation. 1999;99:1972-7.
3. Ito H, Tomooka T, Sakai N, Yu H, Higashino Y, Fujii K, et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation. 1992;85:1699-705.
4. Somitsu Y, Nakamura M, Degawa T, Yamaguchi T. Prognostic value of slow resolution of ST-segment elevation following successful direct percutaneous transluminal coronary angioplasty for recovery of left ventricular function. Am J Cardiol. 1997;80:406-10.
5. Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, Vigo F, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol. 2003;42:1879-85.
6. Antoniucci D, Migliorini A, Parodi G, Valenti R, Rodriguez A, Hempel A, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation. 2004;109:1704-6.
7. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998;98:734-41.
8. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-903.
9. Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;35:915-21.
10. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-66.
11. Petronio AS, Musumeci G, Limbruno U, De Carlo M, Baglini R, Paterni G, et al. Abciximab improves 6-month clinical outcome after rescue coronary angioplasty. Am Heart J. 2002;143:334-41.
12. Bar FW, Volders PG, Hoppener P, Vermeer F, Meyer J, Wellens HJ. Development of ST-segment elevation and Q- and R- wave changes in acute myocardial infarction and the influence of thrombolytic therapy. Am J Cardiol. 1996;77:337-43.
13. Samson WE, Scher AM. Mechanism of S-T segment alteration during acute myocardial injury. Circ Res. 1960;8:780-7.
14. Dissmann R, Goerke M, von Ameln H, Rennhak U, Schroeder J, Linderer T, et al. [Detection of early reperfusion and prediction of left ventricular damage from the course of increased ST values in acute myocardial infarct with thrombolysis]. Z Kardiol. 1993;82:271-8.
15. Hlatky MA, Califf RM, Lee KL, Pryor DB, Wagner GS, Rosati RA. Prognostic significance of precordial ST-segment depression during inferior acute myocardial infarction. Am J Cardiol. 1985;55:325-9.
16. Saran RK, Been M, Furniss SS, Hawkins T, Reid DS. Reduction in ST segment elevation after thrombolysis predicts either coronary reperfusion or preservation of left ventricular function. Br Heart J. 1990;64:113-7.
17. Schroder R, Dissmann R, Bruggemann T, Wegscheider K, Linderer T, Tebbe U, et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol. 1994;24:384-91.
18. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349:733-42.
19. Andersen HR, Nielsen TT, Vesterlund T, Grande P, Abildgaard U, Thayssen P, et al. Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2). Am Heart J. 2003;146:234-41.
20. Hindman NB, Schocken DD, Widmann M, Anderson WD, White RD, Leggett S, et al. Evaluation of a QRS scoring system for estimating myocardial infarct size. V. Specificity and method of application of the complete system. Am J Cardiol. 1985;55:1485-90.
21. Juergens CP, Fernandes C, Hasche ET, Meikle S, Bautovich G, Currie CA, et al. Electrocardiographic measurement of infarct size after thrombolytic therapy. J Am Coll Cardiol. 1996;27:617-24.
22. Vejlstrup N, Clemmensen P, Steinmetz E, Krusell LR, Hansen KN, Christiansen I, et al. on behalf of the DANAMI-2 investigators. Blinded end point adjudication in the Danish multicenter randomized stuy on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction (DANAMI-2 trial). Heart Drug. 2003;3:127-33.
23. de Lemos JA, Antman EM, Gibson CM, McCabe CH, Giugliano RP, Murphy SA, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation. 2000;101:239-43.
24. Armstrong PW, Wagner G, Goodman SG, Van de WF, Granger C, Wallentin L, et al. ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. Eur Heart J. 2003;24:1515-22.
25. Gyongyosi M, Domanovits H, Benzer W, Haugk M, Heinisch B, Sodeck G, et al. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. Eur Heart J. 2004;25:2125-33.
26. Thygesen K, Horder M, Nielsen BL, Peterson PH. Evolution of ST segment and Q and R waves during early phase of inferior myocardial infarction. Acta Med Scand. 1979; 205:25-30.
27. Thygesen K, Horder M, Petersen PH, Nielsen BL. Praecordial ECG mapping in acute anterior myocardial infarction. The evolution of ST segment and Q and R waves. Acta Med Scand. 1981;209:161-7.
28. Eisenberg MJ, Jamal S. Glycoprotein IIb/IIIa inhibition in the setting of acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2003;42:1-6.
29. Araújo J, Veloso H, Paiva J, Filho M, De Paola A. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: A meta-analysis of randomized, controlled trials. Am Heart J. 2005;148:937-43.
30. Kong DF, Hasselblad V, Harrington RA, White HD, Tcheng JE, Kandzari DE, et al. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol. 2003;92: 651-5.
31. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001; 357:1905-14.
32. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605-13.